Want to see TLRY full AI Analyst Report?
TLRY Stock Chart & Stats
$4.64
$0.15(3.87%)
At close: 4:00 PM EDT
$4.64
$0.15(3.87%)
Day’s Range― - ―
52-Week Range$3.67 - $23.20
Previous Close$4.04
Volume3.69M
Average Volume (3M)3.72M
Market Cap
$547.54M
Enterprise Value$780.77
Total Cash (Recent Filing)$231.27M
Total Debt (Recent Filing)$398.40M
Price to Earnings (P/E)―
Beta1.07
Next Earnings
Oct 01, 2026EPS Estimate
-0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.33
Shares Outstanding136,203,580
10 Day Avg. Volume3,213,297
30 Day Avg. Volume3,724,499
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)0.38
Price to Sales (P/S)0.67
P/FCF Ratio-6.01
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$6.13Price Target Upside32.00% Upside
Rating ConsensusHold
Number of Analyst Covering4
EPS Forecast (FY)-0.5
Revenue Forecast (FY)$1.12B
Bulls Say, Bears Say
Bulls Say
International Cannabis GrowthStrong international cannabis growth demonstrates expanding demand and improving market penetration across multiple countries. Rising medical flower volumes and increased Portuguese production capacity provide a platform for broader distribution, operating leverage, and continued revenue development over the next several quarters.
Liquidity And Lower LeverageSubstantial liquidity and near-zero net debt give Tilray greater flexibility to fund operations, absorb volatility, and execute its growth plans without immediate reliance on heavy borrowing. Debt reduction also lowers financial pressure and supports a more resilient capital structure.
Distribution Platform StrengthThe distribution business provides meaningful scale and established access to a large pharmacy and wholesaler network. Revenue growth alongside modest gross-margin improvement suggests this platform can support recurring sales, broaden customer reach, and contribute more consistently to company-wide operating leverage.
Bears Say
Persistent Losses And Cash BurnContinued net losses and negative adjusted free cash flow show that Tilray has not yet achieved self-funded operations. Even with year-over-year improvement, ongoing cash burn can constrain investment capacity, increase financing dependence, and make sustained profitability dependent on successful execution.
International Cannabis Price CompressionPrice compression directly reduces the profit contribution of international cannabis growth and makes revenue expansion less valuable when volumes do not translate into comparable gross profit. Persistent pricing pressure could limit margin expansion and require further cost reductions or product-mix improvements.
BrewDog Cash Conversion StrainThe BrewDog acquisition is tying up substantial working capital and delaying cash conversion, increasing pressure on an already cash-burning business. Until inventory, receivables, and integration processes normalize, the transaction may absorb liquidity and reduce the financial benefit of beverage expansion.
Tilray News
TLRY FAQ
What was Tilray’s price range in the past 12 months?
Tilray lowest stock price was $3.67 and its highest was $23.20 in the past 12 months.
What is Tilray’s market cap?
Tilray’s market cap is $547.54M.
When is Tilray’s upcoming earnings report date?
Tilray’s upcoming earnings report date is Oct 01, 2026 which is in 17 days.
How were Tilray’s earnings last quarter?
Tilray released its earnings results on Jul 28, 2026. The company reported -$0.43 earnings per share for the quarter, missing the consensus estimate of -$0.012 by -$0.418.
Is Tilray overvalued?
According to Wall Street analysts Tilray’s price is currently Undervalued.
Does Tilray pay dividends?
Tilray does not currently pay dividends.
What is Tilray’s EPS estimate?
Tilray’s EPS estimate is -0.17.
How many shares outstanding does Tilray have?
Tilray has 136,203,580 shares outstanding.
What happened to Tilray’s price movement after its last earnings report?
Tilray reported an EPS of -$0.43 in its last earnings report, missing expectations of -$0.012. Following the earnings report the stock price went down -0.993%.
Which hedge fund is a major shareholder of Tilray?
Currently, no hedge funds are holding shares in TLRY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tilray Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$6.13 (32.00% Upside)
$6.13 (32.00% Upside)
Blogger Sentiment
Bullish
TLRY Sentiment 67%
Sector Average 61%
Sector Average 61%
Hedge Fund Trend
Decreased
By 359.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $69.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.4%
Last 30 Days ▼ 7.0%
Last 30 Days ▼ 7.0%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-62.07%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
11.31%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Tilray
Tilray Brands, Inc. is a diversified global consumer packaged goods company primarily involved in the cultivation, processing, marketing, and sale of cannabis products. Its operations span a significant international footprint, encompassing Canada, the United States, Europe, Australia, New Zealand, and Latin America. The company organizes its business across four distinct divisions: Cannabis, Distribution, Beverage Alcohol, and Wellness. Within its cannabis division, Tilray provides a comprehensive range of medical and adult-use items, including regulated products like GMP-certified cannabis flowers, oils, vaporizers, edibles, and topical applications. Beyond cannabis, Tilray's portfolio extends to the procurement and resale of pharmaceutical and wellness goods. Furthermore, it manufactures, promotes, and distributes a variety of alcoholic beverages, alongside hemp-derived food and other wellness items. The company markets its diverse offerings under numerous recognized brands, such as Tilray, Aphria, SweetWater, and Breckenridge Distillery. Its products reach a wide array of customers, including retail outlets, wholesale partners, medical patients, healthcare practitioners, hospitals, pharmacies, scientific researchers, governmental bodies, and directly to end consumers. Formerly operating as Tilray, Inc., the corporation is headquartered in Leamington, Canada.
TLRY Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted meaningful operational progress: record revenue and adjusted EBITDA, stronger liquidity (≈$235M cash) and near-zero net debt, substantial international cannabis and distribution growth, and strategic beverage expansion through the BrewDog acquisition and the Carlsberg partnership. At the same time, challenges remain including a FY2026 net loss of $105.2M, negative adjusted free cash flow (negative $86M), international price compression (~$21M), legacy U.S. beverage headwinds, and significant working capital tied up in the BrewDog transaction. Overall the company presented a pathway to higher margins and cash generation but still faces execution and market-mix headwinds in the near term.View all TLRY earnings summariesTLRY Stock 12 Month Forecast
Average Price Target
$6.13
▲(32.00% Upside)
Technical Analysis
Ownership Overview
2.19% Insiders
0.36% Mutual Funds
0.78% Other Institutional Investors
93.53% Public Companies and
Individual Investors